Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer

Min Che Tung, Chin Shaw Stella Tsai, Jai Nien Tung, Tang Yi Tsao, Hung Chang Chen, Kun Tu Yeh, Ching Fong Liao, Ming Chung Jiang

研究成果: 雜誌貢獻文章同行評審

30 引文 斯高帕斯(Scopus)


Metastatic markers are highly useful diagnostic and prognostic indicators of cancer metastasis. Herein, we report that secretory CSE1L/CAS, a cellular apoptosis susceptibility protein, is a new marker for metastatic cancer. CAS was colocalized with matrix metalloproteinase-2 in vesicles surrounding the outside of MCF-7 cell membranes, and the COOH-terminal domain of CAS was associated with matrix metalloproteinase-2-containing vesicles. Immunohistochemical staining for CAS was positive in the stroma and gland lumens of human metastatic cancer tissues. CAS was also detected in conditioned medium from B16-F10 melanoma cells and more frequently in the sera of patients with metastatic cancer than in sera from patients with primary cancer. Specifically, the prevalence of serum CAS in serum samples from 146 patients was 58.2% (32 of 55), 32.0% (8 of 25), and 12.1% (8 of 66) for patients with metastatic, invasive, and primary cancers, respectively. Our results suggest that CAS is a secretory protein associated with cancer metastasis, which may have clinical utility in metastatic cancer screening and diagnosis.
頁(從 - 到)1570-1577
期刊Cancer Epidemiology Biomarkers and Prevention
出版狀態已發佈 - 5月 2009

ASJC Scopus subject areas

  • 流行病學
  • 腫瘤科


深入研究「Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer」主題。共同形成了獨特的指紋。